Merck & Company, Inc. · NYSE:MRK
Merck & — Investor Day (2019)
7 slides from Merck &'s investor day presentation, 2019
Slide 1: Merck Investor Day
Merck Day INVENTING FOR LIFE
Slide 2: Forward-Looking Statement
FORWARD-LOOKING STATEMENT OF MERCK & Co., Inc., Kenilworth, N.J., USA These presentations from Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) include “forward- looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.
Slide 3: Today's Agenda
TODAY’S AGENDA Welcome & Introductions Ken Frazier, Chairman and Chief Executive Officer Financial & Value Creation Overview Rob Davis, Chief Financial Officer and Head of Global Services Commercial Growth Drivers: KEYTRUDA & Beyond Frank Clyburn, Chief Commercial Officer Animal Health Innovation Ri
Slide 4: After more than years, our mission remains as critical as ever
AFTER MORE THAN 125 YEARS, OUR MISSION REMAINS AS CRITICAL AS EVER To discover, develop and provide innovative products Ken Frazier and services that save and improve lives around the world Premier science-driven biopharmaceutical company 4
Slide 5: Today's Industry Landscape
TODAY’S INDUSTRY LANDSCAPE CHALLENGES OPPORTUNITIES Rising cost of High unmet medical needs healthcare and R&D of patients globally Pricing policy uncertainty Growing and aging and shift to outcome-based global population reimbursement in the U.S. New modalities Ken Frazier Increased molecular and t
Slide 6: Evolution at Merck over the last 5 years
EVOLUTION AT MERCK OVER THE LAST 5 YEARS Revitalized focus on science-driven, integrated approach to R&D Solidified leadership across key pillars of growth Strengthened operating model to drive execution globally Ken Frazier Built energized leadership team and deep bench of talent Strong momentum fo
Slide 7: Clear Strategic Priorities to Drive Continued Leadership
CLEAR STRATEGIC PRIORITIES TO DRIVE CONTINUED LEADERSHIP Advance Unlock full Drive Deliver Ken Frazier pipeline for commercial simplification sustainable, ongoing scientific potential of and culture profitable breakthroughs portfolio change growth 7